299 related articles for article (PubMed ID: 12871130)
1. Perspectives on the cardioprotective effects of statins.
Luo JD; Chen AF
Curr Med Chem; 2003 Aug; 10(16):1593-601. PubMed ID: 12871130
[TBL] [Abstract][Full Text] [Related]
2. Beneficial cardiovascular pleiotropic effects of statins.
Davignon J
Circulation; 2004 Jun; 109(23 Suppl 1):III39-43. PubMed ID: 15198965
[TBL] [Abstract][Full Text] [Related]
3. Statins: the new aspirin?
Veillard NR; Mach F
Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
Essig M; Vrtovsnik F; Friedlander G
Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
[TBL] [Abstract][Full Text] [Related]
5. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
Igel M; Sudhop T; von Bergmann K
Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
7. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
Balakumar P; Mahadevan N
Br J Pharmacol; 2012 Jan; 165(2):373-9. PubMed ID: 21790534
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction.
Jones SP; Lefer DJ
Acta Physiol Scand; 2001 Sep; 173(1):139-43. PubMed ID: 11678736
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
Singh N; Tamariz J; Chamorro G; Medina-Franco JL
Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805
[TBL] [Abstract][Full Text] [Related]
10. Endothelium-dependent effects of statins.
Wolfrum S; Jensen KS; Liao JK
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):729-36. PubMed ID: 12615672
[TBL] [Abstract][Full Text] [Related]
11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
12. Statins as anti-inflammatory agents.
Weitz-Schmidt G
Trends Pharmacol Sci; 2002 Oct; 23(10):482-6. PubMed ID: 12368073
[TBL] [Abstract][Full Text] [Related]
13. The cardioprotective effects of statins.
Eto M; Lüscher TF
Coron Artery Dis; 2004 Aug; 15(5):243-5. PubMed ID: 15238819
[TBL] [Abstract][Full Text] [Related]
14. Statins and myocardial hypertrophy.
Nakagami H; Liao JK
Coron Artery Dis; 2004 Aug; 15(5):247-50. PubMed ID: 15238820
[TBL] [Abstract][Full Text] [Related]
15. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
16. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Davidson MH
Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
[TBL] [Abstract][Full Text] [Related]
17. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
McCarey DW; Sattar N; McInnes IB
Arthritis Res Ther; 2005; 7(2):55-61. PubMed ID: 15743490
[TBL] [Abstract][Full Text] [Related]
18. Statins: pros and cons.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Med Clin (Barc); 2018 May; 150(10):398-402. PubMed ID: 29292104
[TBL] [Abstract][Full Text] [Related]
19. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
[TBL] [Abstract][Full Text] [Related]
20. Direct vascular effects of HMG-CoA reductase inhibitors.
Laufs U; Liao JK
Trends Cardiovasc Med; 2000 May; 10(4):143-8. PubMed ID: 11239793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
